Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10927184 Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Marcela Maus0

Carl H. June0

Jennifer Brogdon0

John Scholler0

Andreas Loew0

Date of Patent

February 23, 2021

0

Patent Application Number

161923750

Date Filed

November 15, 2018

0

Patent Citations

US Patent 10357514 Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Patent Citations Received

US Patent 11458167 Bispecific CAR T-cells for solid tumor targeting

Patent Primary Examiner

Zachary S Skelding

0

Patent abstract

The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10927184 Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool